Skip to main content
OpenTrials
Completed

NCT Number: NCT03588637

Real-world Daptomycin Use in Chinese ICUs

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Daptomycin Intensive Care Unit Real-world Study

Age range

1 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

West China Hospital

Chengdu, Sichuan, 610041, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who received at least one dose of daptomycin

Exclusion criteria

  • No

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. mortality

    Time frame: 30 days

    death

  2. Cure Rate

    Time frame: 30 days

    clinical and microbiological effectiveness

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Time frame: 30 days

    organ dysfunction，allergy，creatine kinase levels，eosinophilic pneumonia，etc.

Sponsors and collaborators

Lead sponsor

West China Hospital

Other

Registry information

Official study title

Real-world Effectiveness and Safety on Daptomycin in Gram-Positive Infections in Chinese Intensive Care Units

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jul 17, 2018
Registry last updated
Jul 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.